Biofrontera vs Journey Medical
BFRI and DERM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BFRI and DERM compare
Journey Medical is the larger company, worth 9.0 times as much as Biofrontera ($125M against $13.9M).
Journey Medical grew revenue faster over the last twelve months (20.9% versus 17.8% for Biofrontera).
Journey Medical keeps more of each dollar of sales as profit, with a net margin of −9.0% compared with −13.8% at Biofrontera.
Biofrontera scores higher on the StockData Score (9 against 7 for Journey Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BFRI | DERM |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | $125M |
| Share price | $0.938 | $4.44 |
| Change, 1 year | −9.9% | −50.4% |
| Change, 5 years | −98.2% | −49.5% |
| Beta (5Y) | 1.02 | 0.69 |
| Employees | 92 | 58 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 1.8× |
| P/B | 2.3× (better) | 3.9× |
| FCF yield | −57.0% | – |
| Fair value | – | $5.72 |
| Margin of safety | – | 22.3% |
| Growth | ||
| Revenue growth (TTM) | 17.8% | 20.9% (better) |
| Revenue growth, 5Y average | 17.2% (better) | 6.8% |
| Profitability | ||
| Gross margin | – | 65.5% |
| Operating margin | −14.2% | −4.4% (better) |
| Net margin | −13.8% | −9.0% (better) |
| FCF margin | −17.2% | – |
| Return on equity | −988% | −23.8% (better) |
| Return on invested capital | – | −8.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.79 (better) |
| Interest coverage | – | −0.8× |
| Current ratio | 1.18 | 1.59 (better) |
| Altman Z-score | −6.18 | 0.62 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 19.7% | 37.8% |
| Held by insiders | 23.6% | 15.3% |
| Short interest, % of float | – | 12.9% |
Go deeper
- BFRI stock overview
- BFRI income statement
- BFRI valuation and score
- DERM stock overview
- DERM income statement
- DERM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.